On the stock market since 2020, it operates in the world of health and science. It has 1,523 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 9% a year over the last 4 years. Every year shown ended in profit.
The gap is $88.5M. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
An investor who bought at the very peak is down 83% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
The stock sits at $0.14. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Over the last 3 years, sales grew only 1% a year on average. At this size, speeding back up is not easy.
The company’s market value is 40 times its annual profit. Even a small disappointment could hit the price hard.
On our five-subject report card, FGHQF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: FGHQF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.